Dopamine D2 Agonist Market Size, Share, Growth, Trends, and Global Industry Analysis: Assessment and Forecast – Competition Landscape, Commercial, and Pipeline Analysis, 2023-2029

Dopamine D2 receptors are members of the heptahelical G protein–coupled receptor superfamily, and they activate the α1 subunits, which leads to inhibition of cyclic adenosine monophosphate (cAMP) synthesis. A dopamine agonist (DA) is a compound that activates dopamine receptors. There are two families of dopamine receptors, D2-like and D1-like and they are all G protein-coupled receptors. Dopamine receptor D2, also known as D2R, is a protein that, in humans, is encoded by the DRD2 gene. Dopamine receptor DRD2, functions to regulate synthesis, storage and release of dopamine. Mutations in the DRD2 gene can inhibit dopamine production and activity, leading to psychiatric and psychotic effects as well as an increased risk for addiction and neuropsychiatric diseases. Dopamine D2 receptor activation induces pathways involved in cell differentiation, growth, metabolism, and apoptosis. DRD2 Agonists are used to treat CNS disorders, movement disorders, brain diseases, neurodegenrative diseases, psychotic disorders, dyskinesias, Parkinson diseases, neuromuscular diseases, rheumatic diseases, schizophrenia, sleep disorder, Alzheimer diseases, bipolar disorders, delirium, dementia, depression, and obesity among others. According to the World Health Organization 2022, Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults. It is not as common as many other mental disorders. Onset is most often during late adolescence and the twenties, and onset tends to happen earlier among men than among women. launch of newer products by the market players significantly enhances the revenue of DRD2 Agonists market over the forecast years. For instance, Salix Pharmaceuticals cycloset (bromocriptine mesylate) for the treatment of type 2 diabetes mellitus. Sunovion Pharmaceuticals Kynmobi (apomorphine hydrochloride) for treatment of Parkinson disease. Boehringer Ingelheim’s Mirapex (pramipexole dihydrochloride) for the restless legs syndrome. Development of other molecules by many market player are coming up with more treatment options. For instance, Newron’s sarizotan (EMD128130) for the antipsychotic effect, UCB’s rotigotine intransal (SPM 952) for Parkinson disease are under the various stages of clinical studies.

Key Market Developments:

• In May 2020, FDA has approved Sunovion’s Kynmobi (apomorphine hydrochloride) sublingual film for the treatment of parkinson disease.
• In December 2022, FDA has approved Abbvie’s Vraylar (cariprazine) as an adjunctive therapy for the treatment of major depressive disorder (MDD) in adult.

Approved Drug Molecules for DRD2 Agonist along with the Brand Names:

• Cycloset (bromocriptine mesylate)
• Kynmobi (apomorphine hydrochloride)
• Mirapex (pramipexole dihydrochloride)
• Vraylar (cariprazine)
• Neupro (rotigotine transdermal)
• Aristada (aripiprazole lauroxil)
• Norprolac (quinagolide)
• Teluron (terguride)
• Domin (talipexole)

Drugs under the Pipeline for DRD2 Agonist:

• Rotigotine XR Microspheres (LY03003)
• Sarizotan (EMD128130)
• Quinagolide Vaginal Ring (FE-999051)
• Lu AF28996
• Pramipexole/Rasagiline (P2B001)
• Rotigotine Intranasal (SPM 952)
• Pramipexole ER (CTC-413)
• Pramipexole Immediate Release (CTC-501)

Clinical Activity and Developments of DRD2 Agonists:

As of June 2023, more than 25 companies have approximately 28 molecules for above 115 diseases. For these molecules, approximately 50 clinical trials are being conducted by the players across the globe. For instance,

• In June 2023, Abbvie conducting 26- week, multicenter, open-label, flexible-dose study to evaluate the long-term safety and tolerability of cariprazine for treatment of pediatric with schizophrenia, bipolar I disorder.
• In February 2023, Chase Therapeutics conducting Phase 2 clinical study of Pramipexole to evaluate safety, tolerability with Aprepitant in patients with idiopathic parkinson disease.